American biotechnology company will use Cuban medicine in clinical trials • Workers

American biotechnology company will use Cuban medicine in clinical trials • Workers
American biotechnology company will use Cuban medicine in clinical trials • Workers
Charging…

By: Karen Márquez Blanco, journalism student

On May 3, 2024, the Biocubafarma business group announced in its X account the approval of the Cuban drug Heberprot-P to be part of a clinical study sponsored by the American biotechnology company Discovery Therapeutics Caribe (DTC).

The trial will be randomized, double-blind and placebo-controlled. According to Lee Weigrat, director of the DTC, if the tests have positive results, it is expected that by 2028 the drug can be marketed in the United States.

After the DTC presented a request to the United States Food and Drug Administration (FDA) in the first quarter of 2024 for the use of the Cuban drug, on April 28 the FDA formally authorized, and for the first time, the use of the drug in the United States.

Developed by the Center for Genetic Engineering and Biotechnology, Heberprot-P is a medication designed to progressively stimulate healing in the lesions of diabetic patients, which reduces the risk of amputation and improves their quality of life.

With the use of this medicine, Cuba managed to reduce the risk of amputation due to diabetic foot ulcer by 78 percent. Lee Weigart also stated that the study will benefit the 38.4 million Americans who suffer from diabetes, of which 1.6 million each year develop diabetic foot ulcers and 160,000 end up in amputation.

 
For Latest Updates Follow us on Google News
 

-

PREV School of Community Leadership and Student Involvement: forging agents of change | UAH
NEXT Change of Pioneer Attribute in honor of Maceo and Che (+photos and post) – Juventud Rebelde